Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development
Avenue Therapeutics, Inc. (ATXI)
Last avenue therapeutics, inc. earnings: 8/14 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.avenuetx.com/investors/investors-home/default.aspx
Company Research
Source: GlobeNewswire
NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, announced today that its Phase 1 data on intravenous (IV) tramadol has been published in the peer-reviewed journal Clinical Pharmacology in Drug Development. Based on the results of the study, Avenue chose the IV tramadol 50 mg dosing regimen for Phase 3 development. The objective of this Phase 1, open-label, single investigational center, three-treatment, three-period, multidose crossover study was to compare the pharmacokinetics of two novel IV tramadol dosing regimens to oral tramadol 100 mg given every six hours, the highest approved oral dosage in the United States. Compared to the oral regimen, IV tramadol 50 mg administered at hours 0, 2, and 4 and every 4 hours thereafter reached initial tramadol peak serum concentration (Cmax) more rapidly, while resulting in similar overall steady-state Cm
Show less
Read more
Impact Snapshot
Event Time:
ATXI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATXI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATXI alerts
High impacting Avenue Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATXI
News
- Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswire
- Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual SummitGlobeNewswire
- Avenue Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
ATXI
Sec Filings
- 11/15/24 - Form SC
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- ATXI's page on the SEC website